unresectable stage III NSCLC
GPTKB entity
Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:stage_III_non-small_cell_lung_cancer
medical condition |
| gptkbp:guidanceSystem |
gptkb:NCCN_Guidelines
gptkb:ESMO_Guidelines |
| gptkbp:hasCancerType |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:hasDiagnosticMethod |
gptkb:CT_scan
PET scan biopsy |
| gptkbp:hasResectability |
unresectable
|
| gptkbp:hasStandardOfCare |
concurrent chemoradiotherapy
durvalumab maintenance |
| gptkbp:hasSurvivalRate |
5-year survival rate 15-30%
|
| https://www.w3.org/2000/01/rdf-schema#label |
unresectable stage III NSCLC
|
| gptkbp:mutationAssociatedWith |
gptkb:ALK_rearrangement
gptkb:EGFR_mutation gptkb:KRAS_mutation |
| gptkbp:prognosis |
poor
|
| gptkbp:riskFactor |
smoking
exposure to radon family history of lung cancer |
| gptkbp:stageName |
stage III
|
| gptkbp:symptom |
weight loss
cough shortness of breath chest pain |
| gptkbp:treatment |
immunotherapy
chemoradiotherapy |
| gptkbp:bfsParent |
gptkb:Durvalumab
|
| gptkbp:bfsLayer |
6
|